(Q39016790)

8 September 2017

1 reference

title

Immunotherapy approaches in the treatment of malignant brain tumors (English)

1 reference

8 September 2017

1 reference

Anastasie M Dunn-Pirio

series ordinal

1

1 reference

PubMed ID

27875627

8 September 2017

Gordana Vlahovic

series ordinal

2

1 reference

PubMed ID

27875627

8 September 2017

language of work or name

English

0 references

publication date

22 November 2016

1 reference

8 September 2017

1 reference

8 September 2017

123

1 reference

8 September 2017

5

1 reference

8 September 2017

734-750

1 reference

CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.

8 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

CNS immune privilege: hiding in plain sight

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Drainage of cells and soluble antigen from the CNS to regional lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Structural and functional features of central nervous system lymphatic vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

A new foreign policy: MHC class I molecules monitor the outside world

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Immunotherapy of diffuse gliomas: biological background, current status and future developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Brain capillary pericytes contribute to the immune defense in response to cytokines or LPS in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Prognostic value of round cell (lymphocyte) infiltration in malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Glioblastoma-derived mechanisms of systemic immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Neutrophil degranulation and immunosuppression in patients with GBM: restoration of cellular immune function by targeting arginase I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Hostile takeover: glioma stem cells recruit TAMs to support tumor progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Physiology and therapeutics of vascular endothelial growth factor in tumor immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Cancer immunoediting: from immunosurveillance to tumor escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Toward effective immunotherapy for the treatment of malignant brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Trial Watch: Glioblastoma vaccine therapy disappointment in Phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

A vaccine targeting mutant IDH1 induces antitumour immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Heat shock proteins: cell protection through protein triage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Reliability of HSP70 (HSPA) expression as a prognostic marker in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Heat shock protein vaccines against glioblastoma: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Establishment of tumor-associated immunity requires interaction of heat shock proteins with CD91.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Cutting edge: CD91-independent cross-presentation of GRP94(gp96)-associated peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Cytomegalovirus as a novel target for immunotherapy of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Consensus on the role of human cytomegalovirus in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Imaging of cellular therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Reducing cell number improves the homing of dendritic cells to lymph nodes upon intradermal vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Interleukin-2 is essential for CD4+CD25+ regulatory T cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

DCVax®-L--developed by Northwest Biotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Oncolytic viruses: a new class of immunotherapy drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Intergeneric poliovirus recombinants for the treatment of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Poliovirus 2A protease induces apoptotic cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Oncolytic poliovirus against malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Oncolytic polio virotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Dendritic cells and macrophages are productively infected by poliovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Pseudoprogression and Immune-Related Response in Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Immunotherapy response assessment in neuro-oncology: a report of the RANO working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

The Evolution of T-cell Therapies for Solid Malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Managing cytokine release syndrome associated with novel T cell-engaging therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Basis of CTLA-4 function in regulatory and conventional CD4(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Ipilimumab and Bevacizumab in Glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

NK cells with KIR2DS2 immunogenotype have a functional activation advantage to efficiently kill glioblastoma and prolong animal survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

T-lymphocyte entry into the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

7 January 2021

Expression and functional activity of heat shock proteins in human glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

7 January 2021

FIRST-IN-HUMAN PHASE I CLINICAL TRIAL OF ONCOLYTIC DELTA-24-RGD (DNX-2401) WITH BIOLOGICAL ENDPOINTS: IMPLICATIONS FOR VIRO- IMMUNOTHERAPY.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

7 January 2021

Oncolytic measles virus strains in the treatment of gliomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

7 January 2021

Poliovirus receptor on human blood cells: a possible extraneural site of poliovirus replication

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

7 January 2021

Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30371

7 January 2021

Identifiers

DOI

10.1002/CNCR.30371

1 reference

8 September 2017

1 reference

PubMed ID

27875627